Corporation to supply drug substances for anti-influenza drugs, Avigan Tablet (favipiravir), for the novel disease, COVID-19.
As COVID-19 continues to spread, the Japanese government has decided to increase its stockpiles of Avigan Tablet, which is expected to be effective against COVID-19, for up to 2 million people, and Fujifilm Corporation has expanded its production system and started increasing its production of Avigan Tablet.
President of Kaneka, Minoru Tanaka said that they have been highly praised by major pharmaceutical manufacturers around the world for their process development capabilities, manufacturing technology, and the quality of pharmaceuticals that have been cultivated over years.
Thus, they believe that it is their social mission to promptly start the supply of drug substances for Avigan Tablet and vows to constantly improve its manufacturing system through capital investment, personnel allocation changes, and production plan adjustments to begin supplying the drug substances in July.
He added that they have already started supplying PCR reagents used for COVID-19 tests via group company Kaneka Eurogentec, based in Belgium.
In addition, the company said it is enhancing its contract manufacturing efforts for a COVID-19 vaccine using technologies such as high-quality mRNA and plasmid DNA and are handling an onrush of inquiries.